Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPI1 | P60174 | 2/20 | 1.00 |
| ▸ | ENO1 | P06733 | 1/20 | 0.48 |
| ▸ | PGD | P52209 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14878232 | 0.78 | TPI1 (0.64) | TPI1PGD | |
| SCHEMBL5485133 | 0.73 | TPI1 (0.56) | TPI1PGD | |
| Phosphoglycolic Acid SCHEMBL20798069 | 0.70 | TPI1 (0.54) | TPI1PGD | |
| Phosphoglycolic Acid SCHEMBL380471 | 0.70 | — | — | |
| SCHEMBL4539343 | 0.70 | HDAC1 (0.58) | TPI1 | |
| SCHEMBL4532834 | 0.70 | HDAC1 (0.58) | TPI1 | |
| SCHEMBL4516679 | 0.70 | HDAC1 (0.58) | TPI1 | |
| SCHEMBL4539071 | 0.70 | HDAC1 (0.58) | TPI1 | |
| SCHEMBL4536587 | 0.70 | HDAC1 (0.58) | TPI1 | |
| SCHEMBL4536068 | 0.70 | HDAC1 (0.58) | TPI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2025-01-16 | — | — | US | claimed |
| EP-4433077-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL Business Ltd (GB) | 2024-09-25 | — | — | EP | claimed |
| WO-2023089313-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2023-05-25 | — | — | WO | claimed |
| WO-2013103780-A1 | COMPOSITIONS AND METHODS TO BOOST ENDOGENOUS ROS PRODUCTION FROM BACTERIA | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-07-11 | — | — | WO | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| US-20050026231-A1 | Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease | AURELIUM BIOPHARMA, INC. | 2005-02-03 | — | — | US | claimed |
| WO-2004080819-A2 | TRIOSEPHOSPHATE ISOMERASE DIRECTED DIAGNOSTICS AND THERAPEUTICS FOR MULTIDRUG RESISTANT NEOPLASTIC DISEASE | AURELIUM BIOPHARMA INC. (CA) | 2004-09-23 | — | — | WO | claimed |
| US-12486513-B2 | Modulation of carbon flux through the meg and C3 pathways for the improved production of monoethylene glycol and C3 compounds | BRASKEM S.A. (BR) | 2025-12-02 | — | — | US | disclosed |
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2025-01-16 | — | — | US | disclosed |
| US-20240392329-A1 | MICROORGANISMS AND METHODS FOR THE PRODUCTION OF OXYGENATED COMPOUNDS FROM HEXOSES | BRASKEM S.A. (BR) | 2024-11-28 | — | — | US | disclosed |
| EP-4433077-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL Business Ltd (GB) | 2024-09-25 | — | — | EP | disclosed |
| US-12006526-B2 | Microorganisms and methods for the production of oxygenated compounds from hexoses | BRASKEM S.A. (BR) | 2024-06-11 | — | — | US | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-0414730-B1 | Chemical Compounds and pharmaceutical compositions capable of releasing a drug | MILLS RANDELL L (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5773592-A | COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED | MILLS RANDELL LEE (US) | 1998-06-30 | — | — | US | disclosed |
| US-5428163-A | Luminides; chemiluminescence; redox system, releasing free drug | MILLS RANDELL L (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0414730-A4 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | — | 1993-06-16 | — | — | EP | disclosed |
| EP-0414730-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | Mills, Randell L. (US) | 1991-03-06 | — | — | EP | disclosed |
| WO-1989009833-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | MILLS RANDELL L (US) | 1989-10-19 | — | — | WO | disclosed |
| US-3919360-A | Phosphoglycolohydroxamic acid and derivatives thereof | RESEARCH CORP | 1975-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | TPI1 2088/4885ENO1 309/4885PGD 229/4885 |
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | POLRMT, TK2, GOT2 | TPI1 574/4885ENO1 2727/4885PGD 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.